Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) was $8.52 for the day, down -1.05% from the previous closing price of $8.61. In other words, the price has decreased by -$1.05 from its previous closing price. On the day, 3.32 million shares were traded. BCRX stock price reached its highest trading level at $8.745 during the session, while it also had its lowest trading level at $8.5.
Ratios:
Our analysis of BCRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.88 and its Current Ratio is at 2.93.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on April 29, 2025, initiated with a Overweight rating and assigned the stock a target price of $20.
On February 25, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $15.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 13 ’24 when Hutson Nancy J sold 7,000 shares for $7.54 per share. The transaction valued at 52,780 led to the insider holds 86,638 shares of the business.
Hutson Nancy J bought 7,000 shares of BCRX for $52,584 on Dec 13 ’24.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 1782810112 and an Enterprise Value of 2409080576. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.54. Its current Enterprise Value per Revenue stands at 4.785 whereas that against EBITDA is 64.288.
Stock Price History:
The Beta on a monthly basis for BCRX is 1.11, which has changed by 0.16037738 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, BCRX has reached a high of $11.31, while it has fallen to a 52-week low of $6.01. The 50-Day Moving Average of the stock is -13.94%, while the 200-Day Moving Average is calculated to be 2.01%.
Shares Statistics:
BCRX traded an average of 4.61M shares per day over the past three months and 2964040 shares per day over the past ten days. A total of 209.21M shares are outstanding, with a floating share count of 201.70M. Insiders hold about 3.61% of the company’s shares, while institutions hold 86.09% stake in the company. Shares short for BCRX as of 1749772800 were 23076302 with a Short Ratio of 5.90, compared to 1747267200 on 20977946. Therefore, it implies a Short% of Shares Outstanding of 23076302 and a Short% of Float of 11.07.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A comprehensive evaluation of Biocryst Pharmaceuticals Inc (BCRX) is underway, with the input of 5.0 analysts contributing to its current rating.The consensus estimate for the next quarter is $0.05, with high estimates of $0.13 and low estimates of $0.02.
Analysts are recommending an EPS of between $0.35 and $0.06 for the fiscal current year, implying an average EPS of $0.14. EPS for the following year is $0.57, with 6.0 analysts recommending between $0.84 and $0.3.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 7 analysts. It ranges from a high estimate of $150M to a low estimate of $143.07M. As of the current estimate, Biocryst Pharmaceuticals Inc’s year-ago sales were $109.33MFor the next quarter, 7 analysts are estimating revenue of $156.7M. There is a high estimate of $158.6M for the next quarter, whereas the lowest estimate is $153.75M.
A total of 7 analysts have provided revenue estimates for BCRX’s current fiscal year. The highest revenue estimate was $620.84M, while the lowest revenue estimate was $600.13M, resulting in an average revenue estimate of $608.13M. In the same quarter a year ago, actual revenue was $450.71MBased on 7 analysts’ estimates, the company’s revenue will be $667.58M in the next fiscal year. The high estimate is $699.88M and the low estimate is $625.6M.
